KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Vertex Pharmaceuticals (VRTX) FCF Margin (2016 - 2025)

Historic FCF Margin for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q3 2025 value amounting to 37.04%.

  • Vertex Pharmaceuticals' FCF Margin fell 99300.0% to 37.04% in Q3 2025 from the same period last year, while for Sep 2025 it was 28.47%, marking a year-over-year increase of 388700.0%. This contributed to the annual value of 7.17% for FY2024, which is 409800.0% down from last year.
  • As of Q3 2025, Vertex Pharmaceuticals' FCF Margin stood at 37.04%, which was down 99300.0% from 31.28% recorded in Q2 2025.
  • Vertex Pharmaceuticals' 5-year FCF Margin high stood at 49.47% for Q2 2022, and its period low was 144.49% during Q2 2024.
  • For the 5-year period, Vertex Pharmaceuticals' FCF Margin averaged around 26.21%, with its median value being 42.56% (2022).
  • In the last 5 years, Vertex Pharmaceuticals' FCF Margin tumbled by -1876000bps in 2024 and then soared by 1757700bps in 2025.
  • Vertex Pharmaceuticals' FCF Margin (Quarter) stood at 45.03% in 2021, then increased by 1bps to 45.37% in 2022, then tumbled by -85bps to 7.01% in 2023, then soared by 141bps to 16.9% in 2024, then surged by 119bps to 37.04% in 2025.
  • Its FCF Margin was 37.04% in Q3 2025, compared to 31.28% in Q2 2025 and 28.09% in Q1 2025.